Background
==========

We have previously developed an innovative vaccine based on the genetic mutability and diversity of variable HIV-1 epitopes. This polyvalent peptide vaccine has been shown to induce a broadly reactive peripheral immune response in mice and macaques (Azizi A, J. Immunol, 2008). Our group recently developed a lipid-based vesicle as an oral vaccine delivery system for the induction of mucosal immunity within mucosal tissues. In this study, we take advantage of this technology to entrap our HIV-1 vaccine into this lipid-based vesicle. We then evaluated the ability of our vaccine formulations to induce maturation of mouse dendritic cells. In vitro experiments have shown our liposomally-delivered candidate vaccine to be effective in inducing the maturation of mouse dendritic cells, as demonstrated by increased cell surface MHCII and CD86 expression.

Methods
=======

Mice were sacrificed and bone marrow from femur, tibia and humerus was collected. Marrow cells were then cultured in the presence of IL-4 and GM-CSF for 5 days before being loaded with antigen to induce maturation. The presence of cell surface markers related to dendritic cell maturation was then evaluated by flow cytometry.

Results
=======

Stimulation of immature bone marrow-derived murine dendritic cells with liposomally-delivered HIV peptides induces maturation of these cells, as determined by increased expression of cell-surface markers MHCII and CD86.

Conclusion
==========

Our data indicate that the incorporation of multiple HIV-1 epitopes into a lipid-based delivery system is effective in inducing the maturation of murine dendritic cells. Our findings suggest that a liposomal-based delivery system may act as an effective delivery vehicle.
